ULTIMATE
最终的
基本信息
- 批准号:10625279
- 负责人:
- 金额:$ 81.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAdrenal Cortex HormonesAdverse effectsAffectAnti-Inflammatory AgentsBacterial MeningitisBiologicalBloodBrainCellsCerebrospinal FluidCessation of lifeCharacteristicsClinicalClinical ResearchCollaborationsCryptococcal MeningitisDataDevelopmentDiseaseFutureGeneticGenetic FingerprintingsGenotypeHIVHIV InfectionsHIV therapyHeterogeneityIndividualIndonesiaInfectionInflammationInflammatory ResponseKnowledgeKynurenineLifeLinkMeasuresMeningeal TuberculosisMeningitisMetabolicMetabolic PathwayMetabolismMorbidity - disease rateMycobacterium tuberculosisNetherlandsNeurological outcomeNutrientOutcomePathogenesisPathway interactionsPatientsPersonsPlacebosQuantitative Trait LociRandomizedRandomized, Controlled TrialsRegulationResearch InfrastructureSamplingSerumSeveritiesSpecimenSystems BiologyTechnologyTestingTherapeuticTimeTryptophanTryptophan Metabolism PathwayTuberculosisVietnamWorkbiomarker identificationbrain magnetic resonance imagingcell typeclinical phenotypeco-infectioncohortdata integrationdiagnostic biomarkergenetic variantgenome sequencinggenome-wideimmune functionimmunopathologyimprovedinter-individual variationmetabolic profilemetabolomemetabolomicsmortalitymultiple omicsnovelparticipant enrollmentphenotypic datapredictive markerpreventresponsesample archivesurvival predictiontargeted treatmenttranscriptome sequencingtranscriptomicstreatment and outcometreatment responsetuberculosis treatmentwhole genome
项目摘要
Project Summary/abstract
Tuberculous meningitis (TBM) has a very high mortality, especially in HIV-infected patients, and there is an
urgent need to improve treatment. Intracerebral inflammation has long been recognized as an important
determinant of TBM outcome and adjunctive anti-inflammatory corticosteroid treatment have been shown to
prevent death, but not disability, in HIV-uninfected people with TBM. Corticosteroids represent the only host
directed therapy of proven benefit in tuberculosis treatment, yet their effect is modest, their adverse effects
substantial, and the mechanism by which they reduce mortality is unknown. Furthermore, there is evidence for
heterogeneity in their effect, dependent upon inter-individual variation in the intracerebral inflammatory
response; and whether those with HIV-infection benefit from corticosteroids remains uncertain.
Cellular metabolism is critical for the function of immune cells. We recently found that high concentrations of
cerebrospinal fluid (CSF) tryptophan strongly predicted mortality in Indonesian TBM patients. Using genome-
wide SNP analysis we identified 11 quantitative trait loci that were associated with both CSF tryptophan
concentrations and survival in a separate patient cohort. Many questions remain. How is tryptophan
metabolism altered during TBM? How does it correlate with inflammation, immunopathology, and response to
corticosteroids? How is tryptophan metabolism genetically regulated? Lastly, and very importantly, what is the
effect of HIV co-infection on tryptophan metabolism before and during TBM treatment?
Our aim is to address these questions by integrating data and specimens from large studies in Vietnam and
Indonesia with state-of-the-art omics technology and systems biology in the Netherlands and USA. Based on
our previous study findings ULTIMATE’s first aim is to define tryptophan metabolism in 1500 TBM patients and
300 controls with other brain infections from previous studies in Indonesia and Vietnam, using state-of-the-art
LC-MS platforms. Our second aim is to define the genetic regulation of tryptophan metabolism in TBM with a
combination of genome-wide SNP-typing of DNA from the same patient group and whole genome sequencing
of a subset (n=200). Our third aim is to identify biomarkers predicting the effect of corticosteroids, and discover
potential new targets for host-directed therapy by integrating clinical and neuroradiological data with CSF
transcriptomics, metabolomics, and host genotyping of 600 patients randomized to corticosteroids or placebo.
We will address these 3 aims in HIV-infected and uninfected patients because HIV-associated TBM has higher
mortality and different immunopathology.
Our strong preliminary data, unique access to two large bioarchives and on-going randomized controlled trials
in TBM, and expertise in integration of large-scale clinical and multi-layer ‘omics’ data promises to provide a
step-change in understanding TBM pathogenesis and discovery of new targets for future host-directed
therapies.
项目总结/文摘
项目成果
期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tryptophan metabolism determines outcome in tuberculous meningitis: a targeted metabolomic analysis.
色氨酸代谢决定结核性脑膜炎的结果:靶向代谢组学分析。
- DOI:10.1101/2023.01.08.23284316
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Ardiansyah,Edwin;Pacheco,JulianAvila;Nhat,LeThanhHoang;Dian,Sofiati;Vinh,DaoNguyen;Hai,HoangThanh;Bullock,Kevin;Alisjahbana,Bachti;Netea,MihaiG;Estiasari,Riwanti;Tram,TrinhThiBich;Donovan,Joseph;Heemskerk,Dorothee;Chau,T
- 通讯作者:Chau,T
SARS-CoV-2 RNA in exhaled air of hospitalized COVID-19 patients.
- DOI:10.1038/s41598-022-13008-4
- 发表时间:2022-05-30
- 期刊:
- 影响因子:4.6
- 作者:
- 通讯作者:
Tuberculosis Preventive Therapy for People With Diabetes Mellitus.
糖尿病患者的结核病预防治疗。
- DOI:10.1093/cid/ciab755
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Olomi,Willyhelmina;AndiaBiraro,Irene;Kilonzo,Kajiru;TeBrake,Lindsey;Kibirige,Davis;Chamba,Nyasatu;EliasNtinginya,Nyanda;Sabi,Issa;Critchley,Julia;Sharples,Katrina;Hill,PhilipC;VanCrevel,Reinout
- 通讯作者:VanCrevel,Reinout
Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series.
- DOI:10.1016/j.medj.2021.09.003
- 发表时间:2021-10-08
- 期刊:
- 影响因子:0
- 作者:van Laarhoven A;Kurver L;Overheul GJ;Kooistra EJ;Abdo WF;van Crevel R;Duivenvoorden R;Kox M;Ten Oever J;Schouten J;van de Veerdonk FL;van der Hoeven H;Rahamat-Langendoen J;van Rij RP;Pickkers P;Netea MG
- 通讯作者:Netea MG
Neurological Disease Associated with Chikungunya in Indonesia.
印度尼西亚与基孔肯雅热相关的神经系统疾病。
- DOI:10.4269/ajtmh.22-0050
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Myint,KhinSA;Mawuntu,ArthurHP;Haryanto,Sotianingsih;Imran,Darma;Dian,Sofiati;Dewi,YoraP;Ganiem,AhmadR;Anggreani,Riane;Iskandar,MirnaM;Bernadus,JannoBB;Maharani,Kartika;Susanto,David;Estiasari,Riwanti;Dewi,Hasna;Kristia
- 通讯作者:Kristia
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guy Thwaites其他文献
Guy Thwaites的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Guy Thwaites', 18)}}的其他基金
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 81.35万 - 项目类别: